Ukoniq® (umbralisib) – Drug safety communication
February 3, 2022 - The FDA announced that they are investigating a possible increased risk of death with TG Therapeutics’ cancer medicine, Ukoniq (umbralisib), approved to treat two specific types of lymphomas (marginal zone lymphoma [MZL] and follicular lymphoma [FL]).
Top